Gb Sciences Inc. (OTCMKTS: GBLX) has finalized the sale of the last remaining cannabis facility, completing its transition to the biopharmaceutical sector. Gb Sciences turns its...
GB Sciences Inc (OTCMKTS:GBLX) announced in June that it was awarded an exclusive license to develop, produce and sell oral thin films infused with cannabis. The...
GB Sciences Inc.’s (OTCMKTS:GBLX) subsidiary GBS Global Biopharma Inc. in partnership with National Research Council (NRC) Canada has announced preclinical studies on the company’s proprietary chronic...
Teams from the LSU AgCenter and GB Sciences Inc (OTCMKTS:GBLX) are working with Louisiana pharmacists who intend to serve patients under The Louisiana Medical Cannabis Program...
In 205, the State of Louisiana developed one of the very first pro-cannabis legislations. The legislations allow administration of medical cannabis though within stated conditions. As...
Living with conditions such as asthma, urinary cystitis, peripheral neuropathy, chronic inflammatory pain conditions and hearing loss is quite challenging. GB Sciences Inc (OTCMKTS:GBLX) wants to intervene...
GB Sciences Inc (OTCMKTS:GBLX) has submitted a patent application for Cannabis-based Therapies. The company aims to use the Cannabis-based Therapies for the treatment of neuropathic, inflammatory,...
